Hannah Clarke

Phase 3 BOND-003 data published in Lancet Oncology showed that intravesical cretostimogene grenadenorepvec produced durable complete responses and a favorable safety profile in patients with high-risk, BCG-unresponsive NMIBC with CIS.

Darlifarnib plus cabozantinib demonstrated encouraging antitumor activity with a manageable safety profile in patients with ccRCC, including both cabozantinib-naive and cabozantinib-exposed populations.

CAPTAIN trial data showed TULSA preserved penile length, continence, and erectile function compared with robotic prostatectomy in localized prostate cancer.

The PDUFA target action date is in the fourth quarter of 2026.

The study showed that perioperative EV–pembrolizumab improved EFS, OS, and pCR rate vs neoadjuvant cisplatin-gemcitabine in patients with MIBC who are eligible for cisplatin-based chemotherapy.

Olaparib's indications in the US include use as a single agent for patients with HRR gene-mutated mCRPC and in combination with abiraterone and prednisone for patients with BRCA-mutated mCRPC.

These results provided the basis for the ongoing randomized phase 3 ProstACT Global trial evaluating 177Lu-rosopatamab tetraxetan in mCRPC.

This marks the first phase 3 study of a targeted radiopharmaceutical therapy in clear cell renal cell carcinoma.

Results from a first-in-human phase 0 feasibility trial showed that combined bladder and kidney transplantation was technically feasible.

The Department of Defense will begin annual testosterone deficiency screening for service members aged 30 years and older.

The phase 2 study is assessing whether an adaptive treatment approach can improve responses and enable treatment pauses for select patients.

The pivotal phase 3 Himalayas-1 trial will evaluate rinzimetostat plus darolutamide vs with physician's choice of an ARPI or docetaxel.

According to the authors, the findings lay the groundwork for future work of genomics-guided treatment de-escalation in prostate cancer.

This decision extends the indication for pembrolizumab plus enfortumab vedotin to all patients with MIBC who are candidates for cystectomy.

The phase 1 trial is assessing the safety and preliminary antitumor activity of actinium (225Ac) rhPSMA-10.1 injection.

FDA clearance of the IND for UGN-501 paves the way for a first-in-human phase 1 trial evaluating its safety and feasibility in patients with NMIBC.

The findings suggest that a significant proportion of participants may benefit from discontinuing tamsulosin.

A recent meta-analysis suggests that the Prolaris combined clinical risk score is prognostic across NCCN risk groups in men with localized prostate cancer.

Data from the ARC-20 study are the first to link HIF-2a inhibitor-associated changes in circulating serum EPO, tumor biology, and clinical activity.

These results are intended to support a premarket approval submission for an expanded indication of the Vanquish device for the management of clinically localized prostate cancer.

A recap of the FDA submissions and regulatory decisions in urology from June 2026.

A roundup of the key stories on benign urologic conditions from the second quarter of 2026.

A roundup of the key stories across genitourinary cancers from the second quarter of 2026.

Interim results from the phase 2 CONVERGE-01 trial showed encouraging antitumor activity and a manageable safety profile with Ac-225 rosopatamab tetraxetan in mCRPC.

The tentative approval spans tablets in 40-mg, 80-mg, 120-mg, and 160-mg strengths.

The following FAQs highlight key recommendations and practical takeaways from the 2026 AUA/SUO Advanced Prostate Cancer Guideline.

The NCCN recommends that clinicians consider using ctDNA-MRD testing to stratify risk and guide the use of adjuvant immunotherapy in patients who have not previously received an immune checkpoint inhibitor.

This decision marks the first approval of a PD-1 inhibitor plus antibody-drug conjugate regimen in the EU.

Enzalutamide plus talazoparib showed promising clinical activity in high-volume mHSPC, although with a notable toxicity burden.

The agency is requesting a removal of the limitation of use for age-related hypogonadism as well as updated warnings related to prostate cancer risk and benign prostatic hyperplasia.